Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR - Get Free Report) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 10,400 shares, a decline of 48.8% from the November 30th total of 20,300 shares. Based on an average daily trading volume, of 7,400 shares, the short-interest ratio is presently 1.4 days.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a report on Tuesday, December 17th. Jefferies Financial Group assumed coverage on Pharming Group in a research note on Monday, December 9th. They set a "buy" rating and a $14.00 price objective on the stock. Finally, Oppenheimer decreased their target price on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, October 28th.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,110 shares of the company's stock after acquiring an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.

Pharming Group Stock Performance

NASDAQ PHAR traded down $0.38 during trading on Friday, reaching $10.22. 6,443 shares of the company's stock were exchanged, compared to its average volume of 5,295. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $13.20. The stock has a market capitalization of $693.27 million, a P/E ratio of -39.31 and a beta of 0.05. The business has a 50 day moving average price of $8.47 and a 200-day moving average price of $8.21. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.